OBJECTIVE: To evaluate whether very early treatment in our @entity1 would result in better clinical outcomes and to compare these data with other @entity13785 ( @entity13785 ) cohort studies. METHODS: In this nationwide program, 669   797 newborns were screened for @entity13785 . We diagnosed @entity13785 in 14 of these newborns, and all were treated and followed in our hospital. RESULTS: After 2010, the mean age at first enzyme-replacement therapy (ERT) was 11.92  days. Our @entity1 had better biological, physical, and developmental outcomes and lower anti-rh acid a-glucosidase antibodies after 2  years of treatment, even compared with one group that began ERT just 10  days later than our cohort. No @entity1 had a @entity2167 or @entity227 . The mean age for independent walking was 11.6      1.3  months, the same age as normal @entity1 . CONCLUSIONS: ERT for @entity1 with @entity13785 should be initiated as early as possible before irreversible damage occurs. Our results indicate that early identification of @entity1 with @entity13785 allows for the very early initiation of ERT. Starting ERT even a few days earlier may lead to better @entity1 outcomes.

Very Early Treatment for Infantile-Onset XXXX Contributes to  Better Outcomes.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity227 :: ('MESH:D014786', 'Disease') :: ['abnormal vision'] @entity2167 :: ('MESH:D006311', 'Disease') :: ['hearing disorder'] @entity13785 :: ('MESH:D006009', 'Disease') :: ['infantile-onset Pompe disease', 'IOPD', 'Pompe disease']
@entity13785 :: (MESH:D006009,Disease) :: ['Pompe Disease']
